Pacira BioSciences, Inc.
Pacira BioSciences, Inc. (PCRX): 8 pipeline candidates · 3 upcoming catalysts · ~7 mo cash runway. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
7.2 months
D/E 0.85 · 4% dilution
Lead: Approved
8 candidates
3 upcoming, next in ~1873d
0 buys · 10 sells (180d)
A transparent, data-derived signal for Pacira BioSciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$889.3M
Cash
$144.3M
Quarterly Burn
$122.0M
Runway
7.2 mo
Revenue
$177.4M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| Bupivacaine Hydrochloride | Phase 2 |
| bupivacaine liposome injectable suspension | Phase 2 |
| EXPAREL | Approved |
| iovera° | Approved |
| iovera° system | Approved |
| PCRX-201 | Phase 2 |
| ZILRETTA | Approved |
| ZILRETTA (shoulder indication) | Phase 3 |
Upcoming Catalysts (3)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
238
Total value held
$936.6M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 6,735,343 | $152.2M |
| vanguard capital management llc | 3,568,098 | $80.6M |
| vanguard portfolio management llc | 2,501,286 | $56.5M |
| dimensional fund advisors lp | 2,060,597 | $46.6M |
| d. e. shaw & co., inc. | 1,982,724 | $44.8M |
| state street corp | 1,919,610 | $43.4M |
| renaissance technologies llc | 1,825,501 | $41.3M |
| goldman sachs group inc | 1,569,916 | $35.5M |
| morgan stanley | 1,392,548 | $31.5M |
| geode capital management, llc | 1,143,820 | $25.9M |
Showing top 10 of 238 institutional holders of Pacira BioSciences, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Pacira BioSciences, Inc.'s pipeline?
Pacira BioSciences, Inc. (PCRX) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Pacira BioSciences, Inc.'s lead drug candidate?
Pacira BioSciences, Inc.'s most advanced tracked candidate is Bupivacaine Hydrochloride (Phase 2) for Pain, Postoperative.
What is Pacira BioSciences, Inc.'s next catalyst?
Pacira BioSciences, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ZILRETTA" — expected August 4, 2031.
What is Pacira BioSciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Pacira BioSciences, Inc. has approximately 7.2 months of cash runway.
What is Pacira BioSciences, Inc.'s market capitalization?
Pacira BioSciences, Inc.'s market capitalization is approximately $889.3M.
Get the full picture on Pacira BioSciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.